Merck & Co Inc (XBUL:6MK)
лв 97.9 0 (0%) Market Cap: 475.39 Bil Enterprise Value: 520.01 Bil PE Ratio: 20.83 PB Ratio: 5.65 GF Score: 87/100

Merck & Co Inc Investor Day (Virtual) Transcript

May 03, 2021 / 02:00PM GMT
Peter Dannenbaum
Merck & Co., Inc. - VP of IR

Good morning. I'm Peter Dannenbaum, Head of Investor Relations for Merck. Thank you for joining today's virtual investor event. We look forward to providing you with insight into Merck's spin-off of Organon, which will soon be operating as an independent company. As you can see, we have a full agenda, beginning with Rob Davis, who will describe the transaction from Merck's perspective.

Jennifer Halchak
Organon & Co. - VP of IR

You will then hear from the Organon leadership team, who will describe our business strategy and growth opportunities. I'm Jennifer Halchak, and as the newly appointed lead for Investor Relations at Organon, I know I speak for the team when I say we are really looking forward to today's event.

Kevin Ali, Organon's CEO, will kick this off with a high-level strategic overview. And he will be followed by business leaders, who will highlight the opportunities they see in each of their respective areas of responsibility. Matt Walsh, Organon's CFO, will also provide a financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot